Healthy Volunteers
Conditions
Brief summary
This is a randomized, double-blinded, parallel-controlled Phase I study of CMAB807 administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807 Post-change in Manufacturing Site, versus Prolia #Denosumab# in healthy male subjects after a single dose
Detailed description
This is a randomized, double-blind, parallel-controlled, single-dose phase I clinical study in healthy Chinese male subjects. A total of 132 subjects were planned to be enrolled and randomly assigned to the test group or bioequivalence control group in a 1:1 ratio. Subjects in two groups received a single abdominal subcutaneous injection of post-change CMAB807 or Prolia #Denosumab# 60 mg, respectively. Subjects in three groups were observed for 126 days after administration to evaluate similarities in pharmacokinetics, pharmacodynamics, safety, and immunogenicity.
Interventions
BIOLOGICALPost-change CMAB807
for subcutaneous injection only
BIOLOGICALProlia
for subcutaneous injection only
Sponsors
Taizhou Mabtech Pharmaceutical Co.,Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Biological: Post-change CMAB807, Prolia
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive) when sign the informed consent form. 2. Subjects with body weight of ≥50 kg and BMI ≥19 and ≤ 26 kg/m2. 3. Subjects were willing to take effective contraceptive measures throughout the study period (including: physical contraception, surgery, abstinence, etc.,) until at least 6 months after administration. 4. Subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; moreover, subjects can communicate well with researchers and complete the research according to the regulations. 5. Subjects must be informed consent of the study and voluntarily sign ICF (name and time) prior to the study.
Exclusion criteria
1. After medical examination (vital signs, physical examination, electrocardiogram, chest X-radiography, cervical and abdominal Bultrasound, and various laboratory examinations including blood routine, urine routine, blood biochemistry, etc.), any examination item was judged abnormal by the investigator and had clinical significance. 2. Serum calcium level were out of the normal range. 3. QTcF \> 450 ms (12-lead ECG). 4. Inflammation or abnormalities in or around the site of administration. 5. Those who have a history of serious diseases including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, urinary system, digestive system, respiratory system, metabolic and skeletal systems, or currently have any of the above diseases or active infected diseases, or any other disease or medical condition that may interfere with the results of the trial, such as hereditary bleeding tendency, coagulation disorders or history of blood clots or bleeding. 6. Previous diagnosis of bone disorders that the investigator has determined to be clinically significant, or any disease that affects bone metabolism, including but not limited to: malignant tumors (including myeloma), hypothyroidism/hyperthyroidism, hypoparathyroidism/ hyperthyroidism, acromegaly, Cushing's syndrome, hypopituitarism, severe chronic obstructive pulmonary disease, rheumatoid arthritis, osteomalacia, etc. 7. Subjects with past or current osteomyelitis or osteonecrosis of the jaw (ONJ), or risk factors for ONJ, such as dental disease or jaw disease requiring oral surgery, dental surgery; or plan to have dental surgery during the study. 8. Fracture occurred within 6 months prior to signing ICF. 9. Surgery within 6 months prior to signing ICF, or plan to have surgery during the study period. 10. Allergic to two or more drugs or foods, or to any component of the investigational agent. 11. Use of any prescription drug, over-the-counter drug, vitamin or herbal medicine within 30 days prior to signing ICF, or prior use of drugs within 5 half-lives, whichever is longer. 12. Use of any medications that have the potential to affect bone metabolism prior to administration (e.g., bisphosphonate or fluoride, estrogen, selective estrogen receptor modulators, calcitonin, parathyroid hormone, high-dose vitamin D (\> 1000 IU/ day), anabolic steroids, systemic glucocorticoids, or percalcitriol within 6 months) 13. Use of anti-RANKL mab within 12 months, or any biological agent within 3 months prior to signing ICF. 14. Those who have received vaccine within the 4 weeks prior to signing ICF, or who plan to receive live vaccine during the study period. 15. History of drug abuse, or positive urine drug screening. 16. Those who had donated or lost blood at least 200 mL in the 3 months prior to signing ICF, or planned to donate blood during the study. 17. Those who can not tolerate venipunction, has a history of dizziness of needle and blood. 18. Those who have been enrolled in other drug or device clinical studies within 3 months prior to signing ICF. 19. Those who smoked more than 5 cigarettes per day in the 6 months prior to signing ICF and did not cooperate with smoking bans during the study period. 20. Those who consumed more than 14 units of alcohol per week (1 unit = 17.7mL ethanol, i.e., 1 unit = 357mL 5% beer or 43mL 40% liquor or 147mL 12% wine) in the 3 months prior to signing ICF, or not willing to ban alcohol during the study period. 21. Those who excessively daily consumed tea, coffee or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to signing ICF. 22. Those who have special dietary requirements, or can not accept uniform diet 23. Other conditions considered inappropriate to be included in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Concentration of Denosumab | up to 3000 hours | Maximum Concentration of Denosumab After the Single Injection of denosumab |
| Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time | up to 3000 hours | Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Injection of Denosumab |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 3000 Hours | up to 3000 hours | Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 3000 Hours After the Single Injection of Denosumab |
| Time to Maximum Concentration of Denosumab | up to 3000 hours | Time to Maximum Concentration of Denosumab after the Single Injection of Denosumab |
| Half-time | up to 3000 hours | Half-time after the Single Injection of Denosumab |
| Serum type 1 C-telopeptide (CTX1) | up to 3000 hours | CTX1 level in the serum samples from subjects |
| anti-drug antibodies(ADA) | up to 3000 hours | ADA Positive Rate after the Single Injection of Denosumab |
| Neutralization antibodies(Nab) | up to 3000 hours | Neutralizing Antibody Positive Rate after the Single Injection of Denosumab |
| Apparent Volume | up to 3000 hours | Apparent Volume of Distribution after the Single Injection of Denosumab |
| Clearance Rate | up to 3000 hours | Clearance Rate after the Single Injection of Denosumab |
Other
| Measure | Time frame | Description |
|---|---|---|
| Percentage and Severity of Participants with Adverse Events | up to 3000 hours | Total Frequency and Severity of Adverse Events/Serious Adverse Events Within the Whole Time of the Study |
Countries
China
Outcome results
None listed